[go: up one dir, main page]

WO2008065636A3 - Treatment of disease by modulating cf5 protein - Google Patents

Treatment of disease by modulating cf5 protein Download PDF

Info

Publication number
WO2008065636A3
WO2008065636A3 PCT/IE2007/000117 IE2007000117W WO2008065636A3 WO 2008065636 A3 WO2008065636 A3 WO 2008065636A3 IE 2007000117 W IE2007000117 W IE 2007000117W WO 2008065636 A3 WO2008065636 A3 WO 2008065636A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
modulating
treatment
attenuating
cancer cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IE2007/000117
Other languages
French (fr)
Other versions
WO2008065636A2 (en
Inventor
Rosemary O'connor
Katie O'callaghan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College Cork
Original Assignee
University College Cork
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College Cork filed Critical University College Cork
Publication of WO2008065636A2 publication Critical patent/WO2008065636A2/en
Anticipated expiration legal-status Critical
Publication of WO2008065636A3 publication Critical patent/WO2008065636A3/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Agents capable of modulating Cf5 protein activity in an individual are described and find use in the prevention or treatment of a pathology characterised by dysregulated IGF-IR signalling pathways such as cancer, cardiovascular disease, neurodegenerative disease, ischemia (of thrombotic or haemorrhagic origin), pathologies associated with dysfunctional bone remodelling, pathologies associated with dysfunctional tissue remodelling, inflammation and inflammatory disease, autoimmune disorders, infectious disease, renal disease, chronic and acute wounds, tissue damage, and restenosis. Also described is an agent capable of attenuating the Cf5 activity of a cancer cell for use in attenuating the drug/radiation resistance of a cancer cell.
PCT/IE2007/000117 2006-12-01 2007-11-30 Treatment of disease by modulating cf5 protein Ceased WO2008065636A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87208006P 2006-12-01 2006-12-01
US60/872,080 2006-12-01

Publications (2)

Publication Number Publication Date
WO2008065636A2 WO2008065636A2 (en) 2008-06-05
WO2008065636A3 true WO2008065636A3 (en) 2009-09-24

Family

ID=39327036

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IE2007/000117 Ceased WO2008065636A2 (en) 2006-12-01 2007-11-30 Treatment of disease by modulating cf5 protein

Country Status (1)

Country Link
WO (1) WO2008065636A2 (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020042389A1 (en) * 1998-12-03 2002-04-11 Tanja Ligensa IGF-1 receptor interacting proteins
US20040142381A1 (en) * 2002-07-31 2004-07-22 Hubbard Stevan R. Methods for designing IGF1 receptor modulators for therapeutics
US20040213792A1 (en) * 2003-04-24 2004-10-28 Clemmons David R. Method for inhibiting cellular activation by insulin-like growth factor-1
WO2005011673A1 (en) * 2003-07-22 2005-02-10 Instituto Biomar S.A. Use of antitumoral compounds
WO2005035561A1 (en) * 2003-10-14 2005-04-21 University College Cork - National University Of Ireland, Cork Igf-i responsive gene and use thereof
WO2005117936A2 (en) * 2004-05-07 2005-12-15 The University Of North Carolina At Chapel Hill Method for enhancing or inhibiting insulin-like growth factor-i
WO2006100195A1 (en) * 2005-03-21 2006-09-28 Zambon S.P.A. Use of macrolides for treating intestinal inflammation

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020042389A1 (en) * 1998-12-03 2002-04-11 Tanja Ligensa IGF-1 receptor interacting proteins
US20040142381A1 (en) * 2002-07-31 2004-07-22 Hubbard Stevan R. Methods for designing IGF1 receptor modulators for therapeutics
US20040213792A1 (en) * 2003-04-24 2004-10-28 Clemmons David R. Method for inhibiting cellular activation by insulin-like growth factor-1
WO2005011673A1 (en) * 2003-07-22 2005-02-10 Instituto Biomar S.A. Use of antitumoral compounds
WO2005035561A1 (en) * 2003-10-14 2005-04-21 University College Cork - National University Of Ireland, Cork Igf-i responsive gene and use thereof
WO2005117936A2 (en) * 2004-05-07 2005-12-15 The University Of North Carolina At Chapel Hill Method for enhancing or inhibiting insulin-like growth factor-i
WO2006100195A1 (en) * 2005-03-21 2006-09-28 Zambon S.P.A. Use of macrolides for treating intestinal inflammation

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
COLLIS S ET AL: "ENHANCED RADIATION AND CHEMOTHERAPY-MEDIATED CELL KILLING OF HUMAN CANCER CELLS BY SIRNA-SILENCING OF DNA REPAIR FACTORS", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, vol. 44, 1 July 2003 (2003-07-01), pages 375, XP001155167, ISSN: 0197-016X *
FLOYD S ET AL: "The Insulin-like Growth Factor-I-mTOR Signaling Pathway Induces the Mitochondrial Pyrimidine Nucleotide Carrier to Promote Cell Growth", MOLECULAR BIOLOGY OF THE CELL, BETHESDA, MD, US, vol. 18, no. 9, 27 June 2007 (2007-06-27), pages 3545 - 3555, XP009089428, ISSN: 1059-1524 *
LEROITH DEREK ET AL: "The insulin-like growth factor system and cancer.", CANCER LETTERS 10 JUN 2003, vol. 195, no. 2, 10 June 2003 (2003-06-10), pages 127 - 137, XP002522048, ISSN: 0304-3835 *
LIM J -H ET AL: "Bafilomycin induces the p21-mediated growth inhibition of cancer cells under hypoxic conditions by expressing hypoxia-inducible factor-1[alpha]", MOLECULAR PHARMACOLOGY 2006 US, vol. 70, no. 6, 2006, pages 1856 - 1865, XP002496572, ISSN: 0026-895X 1521-0111 *
LOUGHRAN G ET AL: "IDENTIFICATION AND CHARACTERIZATION OF IGF-IR-REGULATED GENES THAT CONTRIBUTE TO THE SURVIVAL, GROWTH, AND MOTILITY OF TUMOUR CELLS", GROWTH HORMONE AND IGF RESEARCH, CHURCHILL LIVINGSTONE, LONDON, GB, vol. 14, no. 2, 1 April 2004 (2004-04-01), pages 105, XP008040610, ISSN: 1096-6374 *
MULKEEN A ET AL: "siRNA-mediated gene silencing in colorectal cancer: A novel anti-angiogenic targeted therapy", JOURNAL OF SURGICAL RESEARCH, ACADEMIC PRESS INC., SAN DIEGO, CA, US, vol. 121, no. 2, 1 October 2004 (2004-10-01), pages 279 - 280, XP004606048, ISSN: 0022-4804 *
O'CALLAGHAN K M ET AL: "CHARACTERISATION OF AN IGF-I RESPONSIVE GENE THAT ENCODES A NEW ENDOSOMAL PROTEIN", MOLECULAR BIOLOGY OF THE CELL, BETHESDA, MD, US, vol. 15, no. SUPPL. S, 1 November 2004 (2004-11-01), pages 322A, XP009081794, ISSN: 1059-1524 *
PUD D ET AL: "The efficacy of the NMDA receptor antagonist amantadine in the treatment of neuropathic cancer pain: A double blind, randomized, placebo-controlled trial", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 33, 1 September 1997 (1997-09-01), pages S53, XP004283485, ISSN: 0959-8049 *
VASILYEVA E ET AL: "Cysteine scanning mutagenesis of the noncatalytic nucleotide binding site of the yeast V-ATPase.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 7 JAN 2000, vol. 275, no. 1, 7 January 2000 (2000-01-07), pages 255 - 260, XP002522047, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2008065636A2 (en) 2008-06-05

Similar Documents

Publication Publication Date Title
IL250767B (en) Compositions and methods for promoting hemostasis and other physiological activities
CL2007002017A1 (en) COMPOUNDS DERIVED FROM [4,5 '] - BIPIRIMIDINIL-6,4'-DIAMINE; PHARMACEUTICAL COMPOSITION; AND USE AS AN INHIBITOR OF THE ACTIVITY OF CINASA IN CANCER DE VEJIGA, CANCER CERVICAL AND MIELOMA MULTIPLE.
TWI341194B (en) Disposable pant-type diaper
EP1908011A4 (en) RECONSTRUCTION STABILIZER AND ACTIVE VISION
RU2599417C3 (en) HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMABLE DEATH 1 PROTECTION (PD-1) AND METHODS OF CANCER TREATMENT USING ANTI-PD-1-ANTI-BODY, INDEPENDENTLY OR IN COMBINATION WITH OTHER IMMUNETURAH AND I And I And I And I, In The Combine, I And I Do Not Allocate To Them, Combined With Other Overarching
WO2008039841A8 (en) Signal analysis in implantable cardiac treatment devices
PL1979050T3 (en) Treatment of peripheral vascular disease using postpartum-derived cells
WO2008011392A3 (en) Proline urea ccr1 antagonists for the treatment of autoimmune diseases or inflammation
EG25359A (en) Disposable diaper.
EP1853158B8 (en) Balanced physiological monitoring and treatment system
IL190841A0 (en) Pharmaceutical compositions and diagnostic methods for inflammatory skin diseases, disorders or conditions
EP2056857A4 (en) Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
EP2266575A3 (en) Use of Norgestimate as a selective inhibitor of TRPC3, TRPC6 and TRPC7 ion channels
ZA200707935B (en) Low density medical bandage substrate, medical bandage, and medical bandaging
WO2008065636A3 (en) Treatment of disease by modulating cf5 protein
AU2006251169A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
GB0504266D0 (en) Harvesting and threshing system
IL197509A0 (en) Therapeutic and/or ameliorating agent for disseminated intravascular coagulation
EP1742602A4 (en) Skin friendly diaper
WO2006124477A3 (en) Combination therapy with inhibitors of hmgb and caspase for the treatment of inflammatory diseases
WO2007086943A3 (en) Wortmannin conjugates and uses thereof
WO2009034464A3 (en) Indole related compounds with physiological activity
FR2918278B1 (en) USE OF OLEOCANTHAL IN THE TREATMENT OF SKIN INFLAMMATION.
HK1108707A (en) Diagnostic and therapeutic agents
BRPI0813099A2 (en) (OXAZOLIDINON-5-IL-METIL) -2-THIOPHEN-CARBOXAMIDES REPLACED AND THEIR USE IN THE BLOOD COAGULATION FIELD

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07827130

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07827130

Country of ref document: EP

Kind code of ref document: A2